학술논문

Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument
Document Type
article
Source
American Journal of Kidney Diseases. 71(2)
Subject
Biomedical and Clinical Sciences
Clinical Sciences
Clinical Research
Pain Research
Polycystic Kidney Disease
Kidney Disease
Chronic Pain
Cost of Illness
Emotional Adjustment
Fatigue
Female
Focus Groups
Humans
Male
Middle Aged
Patient Reported Outcome Measures
Physical Functional Performance
Polycystic Kidney
Autosomal Dominant
Quality of Life
Reproducibility of Results
Surveys and Questionnaires
ADPKD
PRO instrument
Polycystic kidney
autosomal dominant
cystic
disease burden
kidney diseases
pain
patient-centered outcomes
patient-reported outcome
quality of life
Public Health and Health Services
Urology & Nephrology
Clinical sciences
Language
Abstract
BackgroundThe impact of autosomal dominant polycystic kidney disease (ADPKD) on health-related quality of life (HRQoL) is not well understood due to a lack of instruments specific to the condition.Study designContent for a new self-administered patient-reported outcome (PRO) questionnaire to assess ADPKD-related HRQoL was developed through clinical expert and patient focus group discussions. The new PRO instrument was administered to study patients with ADPKD to evaluate its reliability and validity.Setting & participants1,674 adult patients with ADPKD participated in this research: 285 patients in focus groups to generate questionnaire content, 15 patients in debriefing interviews to refine the PRO questionnaire, and 1,374 patients to assess the performance and measurement properties of the PRO questionnaire.OutcomeA new PRO questionnaire.ResultsThe ADPKD Impact Scale (ADPKD-IS), consisting of 14 items representing 3 conceptual domains (physical, emotional, and fatigue) plus 4 additional questions, was developed. The instrument's reliability (regarding internal consistency and test-retest consistency) and validity (content and construct) were supported.LimitationsNeed for more responsiveness testing when more data from clinical use become available over time. Complex concepts such as ADPKD-related pain and impact on a patient's HRQoL need further evaluation.ConclusionsThe ADPKD-IS is a new patient-centric tool that reliably and validly provides a standardized method for assessing HRQoL and overall disease burden in patients with ADPKD.